Cellectis (NASDAQ:CLLS) Shares Pass Above 200-Day Moving Average - Time to Sell?

Key Points

• Cellectis S.A. shares recently surpassed their 200-day moving average, trading at $3.98 after reaching a high of $4.41, marking a significant milestone for the stock.
• Analysts have mixed views on Cellectis, with Barclays raising its target price to $8.00 and maintaining an "overweight" rating, while Weiss Ratings reaffirmed a "sell" rating.
• Despite reporting a miss in earnings with a loss of ($0.24) per share, Cellectis exceeded revenue expectations with $18.19 million during the last quarter.

Cellectis S.A. (NASDAQ:CLLS - Get Free Report)'s share price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $2.18 and traded as high as $4.41. Cellectis shares last traded at $3.98, with a volume of 218,675 shares traded.

Analysts Set New Price Targets

A number of brokerages have commented on CLLS. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Cellectis in a research note on Wednesday, October 8th. Barclays upped their target price on Cellectis from $4.00 to $8.00 and gave the company an "overweight" rating in a report on Friday. Finally, Wall Street Zen upgraded Cellectis to a "hold" rating in a report on Saturday, September 20th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $8.00.

Cellectis Stock Performance

The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.58. The company has a market cap of $251.24 million, a P/E ratio of -4.85 and a beta of 3.10. The business has a fifty day moving average of $3.18 and a 200 day moving average of $2.18.

Cellectis (NASDAQ:CLLS - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.09). The firm had revenue of $18.19 million during the quarter, compared to analysts' expectations of $10.07 million. Cellectis had a negative return on equity of 68.05% and a negative net margin of 100.69%. On average, equities analysts predict that Cellectis S.A. will post -0.46 EPS for the current year.

Institutional Investors Weigh In On Cellectis

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC grew its stake in Cellectis by 132.9% in the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 26,461 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Cellectis by 228.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company's stock worth $5,856,000 after purchasing an additional 3,284,409 shares during the period. Long Focus Capital Management LLC grew its stake in Cellectis by 2.2% in the first quarter. Long Focus Capital Management LLC now owns 4,717,293 shares of the biotechnology company's stock worth $5,849,000 after purchasing an additional 100,000 shares during the period. Finally, OLD Mission Capital LLC purchased a new stake in Cellectis in the first quarter worth $31,000. 63.90% of the stock is owned by hedge funds and other institutional investors.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.